Can tailored brain zaps ease schizophrenia symptoms?
NCT ID NCT07176468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a personalized form of brain stimulation called iTBS can help reduce schizophrenia symptoms in everyday clinic settings. Forty adults with schizophrenia will receive daily iTBS sessions for two weeks, while continuing their usual medications. Researchers will measure changes in symptoms and brain activity using scans and questionnaires.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18-60 years, any gender * Meets DSM-5 criteria for schizophrenia * Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days * Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments Exclusion Criteria: * Active suicidal ideation or behavior * Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma) * Contraindications to MRI or TMS (e.g., metal implants, pacemakers) * Pregnancy or lactation * Receipt of TMS or ECT within the past 6 months * Judged by investigators to be unsuitable for participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
-
Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, 230032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia